Catalyst Wire Dossier Catalyst Wire Dossier

QL1706 (Iparomlimab/Tuvonralimab)

iparomlimab / tuvonralimab
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for QL1706 (Iparomlimab/Tuvonralimab), covering 2025-08-12 to 2025-08-12. Get the full timeline:

Most recent: Clinical Trial Update: Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma [Phase 2]

See pricing